Strategic partnerships LDC maintains a strong network with top pharma and academic partners (AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Roche, J&J Innovation, Semmelweis University, INSERM, McGill) and collaborates on translational drug discovery, presenting ongoing opportunities for co-development and early-access deals.

Expanding collaborations Recent joint programs with Taros Chemicals and IfADo on KyDo technology indicate a growing openness to new alliances and joint ventures, suggesting target outreach to labs and biotech firms seeking translational capabilities and shared risk profiles.

Early- stage focus LDC specializes in converting academic discoveries into lead compounds with initial proof-of-concept in animals, offering a clear value proposition to partners lacking internal translational capabilities or wishing to de-risk early-stage programs.

Therapeutic breadth Portfolio emphasize small molecules and therapeutic antibody discovery across oncology and rare diseases, enabling cross-sell opportunities to pharma companies seeking pipeline diversification and expansion into new modalities.

Resource leverage With a mid-sized team and strong project management and screening infrastructure, LDC can scale partnerships, offering potential for outsourcing, co-development workloads, and flexible commercial arrangements to fit partner timelines.